Carisma Therapeutics (CARM) Projected to Post Quarterly Earnings on Monday

Carisma Therapeutics (NASDAQ:CARM) is expected to be issuing its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $5.42 million for the quarter.

Carisma Therapeutics Stock Performance

Shares of CARM opened at $0.19 on Friday. The company has a 50-day simple moving average of $0.42 and a two-hundred day simple moving average of $0.64. The firm has a market capitalization of $8.01 million, a PE ratio of -0.12 and a beta of 1.56. Carisma Therapeutics has a one year low of $0.17 and a one year high of $2.05. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23.

Analysts Set New Price Targets

A number of research firms have weighed in on CARM. Baird R W lowered shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Robert W. Baird downgraded shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $10.00 to $1.00 in a report on Thursday, December 12th. HC Wainwright reissued a “neutral” rating on shares of Carisma Therapeutics in a report on Monday, December 16th. BTIG Research lowered Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. Finally, Evercore ISI reissued an “in-line” rating and set a $0.70 target price (down previously from $4.00) on shares of Carisma Therapeutics in a research note on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $2.74.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.